Fig. 4.
![Fig. 4. Immunotherapy of lymphoma-bearing mice with BsAb directed to Id, MHC II, or CD19 on the tumors. / Groups of 5 huCD64+ age-matched mice received a treatment schedule as shown in Figure 3. Treatment was as indicated: PBS (●); [huCD64 × CD19] (▵); [huCD64 × MHC II] (■); [huCD64 × Id] (○). Survival was recorded daily. In the A31 model all treatment modalities resulted in a statistically significant increase in survival over PBS-treated controls (P < .02), though only [huCD64 × Id] BsAb–treated cohorts showed long-term survival. Similar results were obtained in at least 3 similar experiments.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/96/10/10.1182_blood.v96.10.3544/5/h82200347004.jpeg?Expires=1725294130&Signature=br3T9r8fyvdkKGjPR50Wh6uajTVD-n6ppv9TiA15oiG4Il2-QZ08jYWcQcK0a43yfaWtrl28wti-TocRCbQIdJfum-ocIYzTumycQBcimG33XI5Ltgw-jYaZqdEWcwMWyTsElFg-YtblYpslEw9t4A1inlGm9sj6SUowYZkoFKk3LXErhJ3r2yA4nitWONwywDpkWg8B5SqvkesrNsP8ErydbExLzz9aEMtM109HSdPfsIbrPZ4RB80emBxGP9i7MUlQjnPFv7vRIw0y58l4k~GZEjjbCmZ5HVSUTKAiuag7x-dXF34UF7HUWuGjRBdgWZuSg8ayo~~7SdosIwJfWw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Immunotherapy of lymphoma-bearing mice with BsAb directed to Id, MHC II, or CD19 on the tumors.
Groups of 5 huCD64+ age-matched mice received a treatment schedule as shown in Figure 3. Treatment was as indicated: PBS (●); [huCD64 × CD19] (▵); [huCD64 × MHC II] (■); [huCD64 × Id] (○). Survival was recorded daily. In the A31 model all treatment modalities resulted in a statistically significant increase in survival over PBS-treated controls (P < .02), though only [huCD64 × Id] BsAb–treated cohorts showed long-term survival. Similar results were obtained in at least 3 similar experiments.
